Phosphate binders that contain aluminum are frequently prescribed to treat hyperphosphatemia in patients with chronic renal failure, but an accumulation of aluminum can lead to osteomalacia. To evaluate the efficacy of calcium carbonate as an alternative phosphate binder, we studied 20 patients maintained on dialysis during three consecutive periods. In period 1, the patients took aluminum hydroxide for a month (mean dose, 5.6 g per day; range, 1.5 to 14.0). In period 2, they took no phosphate binders for a month, and in period 3, they took calcium carbonate (Os-Cal) for two months (mean dose, 8.5 g per day; range, 2.5 to 17). The mean (+/- SE) serum calcium level during period 1 was 9.6 +/- 0.2 mg per deciliter; this decreased slightly (to 9.3 +/- 0.1) during period 2 and increased to 10.0 +/- 0.2 during period 3. The mean (+/- SE) serum phosphorus level during period 1 was 4.8 +/- 0.1 mg per deciliter; this increased to 7.3 +/- 0.3 during period 2, but returned to the control value (4.8 +/- 0.2) during period 3. Six of the 20 patients continued to need aluminum hydroxide during period 3 for satisfactory control of hyperphosphatemia. Calcium carbonate successfully lowered serum phosphorus levels and raised serum calcium levels in the majority of our patients, thereby confirming that this agent may be a satisfactory substitute for traditional phosphate binders that contain aluminum. The possibility that long-term treatment could cause such side effects as metastatic calcification will require further investigation.
This article has been cited by other articles:
Kovesdy, C. P., Mehrotra, R., Kalantar-Zadeh, K.
(2008). Battleground: Chronic Kidney Disorders Mineral and Bone Disease Calcium Obsession, Vitamin D, and Binder Confusion. CJASN
3: 168-173
[Abstract][Full Text]
Savica, V., Calo, L. A., Monardo, P., Santoro, D., Bellinghieri, G.
(2006). Phosphate binders and management of hyperphosphataemia in end-stage renal disease. Nephrol Dial Transplant
21: 2065-2068
[Full Text]
Moe, S. M., Chertow, G. M.
(2006). The Case against Calcium-Based Phosphate Binders. CJASN
1: 697-703
[Abstract][Full Text]
Felsenfeld, A. J., Levine, B. S.
(2006). Milk Alkali Syndrome and the Dynamics of Calcium Homeostasis. CJASN
1: 641-654
[Full Text]
Jindal, K., Chan, C. T., Deziel, C., Hirsch, D., Soroka, S. D., Tonelli, M., Culleton, B. F.
(2006). CHAPTER 3: Mineral Metabolism. J. Am. Soc. Nephrol.
17: S11-S15
[Full Text]
Jean, G., Chazot, C., Charra, B.
(2006). Hyperphosphataemia and related mortality. Nephrol Dial Transplant
21: 273-280
[Full Text]
Coladonato, J. A.
(2005). Control of Hyperphosphatemia among Patients with ESRD. J. Am. Soc. Nephrol.
16: S107-S114
[Abstract][Full Text]
Bushinsky, D. A., Asplin, J. R.
(2005). Thiazides Reduce Brushite, but not Calcium Oxalate, Supersaturation, and Stone Formation in Genetic Hypercalciuric Stone-Forming Rats. J. Am. Soc. Nephrol.
16: 417-424
[Abstract][Full Text]
Hutchison, A. J., Speake, M., Al-Baaj, F.
(2004). Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant
19: 1902-1906
[Abstract][Full Text]
Lund, R. J., Davies, M. R., Brown, A. J., Hruska, K. A.
(2004). Successful Treatment of an Adynamic Bone Disorder with Bone Morphogenetic Protein-7 in a Renal Ablation Model. J. Am. Soc. Nephrol.
15: 359-369
[Abstract][Full Text]
Al-Hejaili, F., Kortas, C., Leitch, R., Heidenheim, A. P., Clement, L., Nesrallah, G., Lindsay, R. M.
(2003). Nocturnal but not Short Hours Quotidian Hemodialysis Requires an Elevated Dialysate Calcium Concentration. J. Am. Soc. Nephrol.
14: 2322-2328
[Abstract][Full Text]
Goodman, W. G.
(2003). Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant
18: iii2-8
[Abstract][Full Text]
McIntyre, C. W., Patel, V., Taylor, G. S., Fluck, R. J.
(2002). A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant
17: 1643-1648
[Abstract][Full Text]
Minutolo, R., Bellizzi, V., Cioffi, M., Iodice, C., Giannattasio, P., Andreucci, M., Terracciano, V., Di Iorio, B. R., Conte, G., De Nicola, L.
(2002). Postdialytic Rebound of Serum Phosphorus: Pathogenetic and Clinical Insights. J. Am. Soc. Nephrol.
13: 1046-1054
[Abstract][Full Text]
Yang, W.-C., Yang, C.-S., Hou, C.-C., Wu, T.-H., Young, E. W., Hsu, C. H.
(2002). An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant
17: 265-270
[Abstract][Full Text]
SALUSKY, I. B., GOODMAN, W. G.
(2001). Adynamic Renal Osteodystrophy: Is There a Problem?. J. Am. Soc. Nephrol.
12: 1978-1985
[Full Text]
MALBERTI, F., MARCELLI, D., CONTE, F., LIMIDO, A., SPOTTI, D., LOCATELLI, F.
(2001). Parathyroidectomy in Patients on Renal Replacement Therapy: An Epidemiologic Study. J. Am. Soc. Nephrol.
12: 1242-1248
[Abstract][Full Text]
Salusky, I. B., Goodman, W. G.
(2000). Managing phosphate retention: is a change necessary?. Nephrol Dial Transplant
15: 1738-1742
[Full Text]
Chertow, G. M., Burke, S. K., Dillon, M. A., Slatopolsky, E.
(1999). Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant
14: 2907-2914
[Abstract][Full Text]
FINCH, J. L., BROWN, A. J., SLATOPOLSKY, E.
(1999). Differential Effects of 1,25-Dihydroxy-Vitamin D3 and 19-Nor-1,25-Dihydroxy-Vitamin D2 on Calcium and Phosphorus Resorption in Bone. J. Am. Soc. Nephrol.
10: 980-985
[Abstract][Full Text]
Previous
